Shionogi to buy rare disease biotech IntraBio for $2B

· Health · Japan · United States

Japan's Shionogi agreed to pay $2 billion upfront to acquire IntraBio, a commercial rare disease biotech based in Austin, Texas. The deal adds IntraBio's oral treatment Aqneursa, already marketed for two inherited conditions, to Shionogi's growing rare disease business. The acquisition continues a wave of pharma M&A, with Shionogi expanding beyond its traditional areas into rare diseases.

Why it matters：Rare disease assets with marketed products remain attractive to pharma buyers seeking growth beyond crowded therapeutic areas.

Key points

  • Shionogi will pay $2 billion upfront for IntraBio.
  • The deal adds Aqneursa, an oral rare disease treatment.
  • IntraBio is based in Austin, Texas.

Sources (original reporting)

More stories from this day